Understanding Chronic Ocular Surface Pain
Chronic ocular surface pain (COSP) affects countless individuals, often leading to frequent visits to eye care professionals. Despite various therapeutic options targeting the ocular surface, many patients report persistent discomfort. Recent research suggests that in certain cases, the origin of this pain may lie within the central nervous system (CNS) rather than the eye itself. This aligns with observations in chronic overlapping pain conditions, where heightened sensory signaling may be responsible for ongoing pain incidents.
Symptom Discordance in COSP Patients
A pivotal aspect of COSP research is the phenomenon of sign and symptom discordance. Some individuals may experience intense pain with minimal observable damage to the ocular surface, while others may present with significant surface changes yet report lower pain levels. This discordance proposes that the degree of pain may correlate with a greater presence of nociplastic pain mechanisms, suggesting an increased involvement of CNS alterations. The concept is echoed in publications from respected health organizations, which link symptom perception to underlying neurological factors.
Investigating Nociplastic Features
An observational study aiming to enroll 200 participants with COSP is set to investigate these nociplastic features through comprehensive clinical phenotyping. Participants will complete validated patient-reported outcome measures alongside standard ocular examinations, effectively linking COSP presentations to associated conditions such as dry eye syndrome. By employing validated tools, the investigation will provide insights into the complex interplay between ocular symptoms and central processing mechanisms.
As part of this approach, a select group of participants will undergo multimodal evoked sensory testing. This testing will encompass pressure, thermal, and visual stimuli, conducted both near the eye and on other body areas. This methodological strategy seeks to uncover broader sensory amplification patterns consistent with nociplastic mechanisms, akin to findings in other chronic pain syndromes like fibromyalgia. Enhanced understanding of these characteristics could inform targeted interventions.
Evaluating Response to Treatment
To further clarify the origins of pain, the study will also assess predictors of treatment response using a topical ocular anesthetic. The expectation is that the administration of a topical anesthetic will obstruct pain primarily induced by peripheral sources, potentially allowing researchers to differentiate between peripheral and centrally-mediated pain drivers. Such distinctions could pave the way for future treatments that target CNS mechanisms directly, offering new hope for patients who do not benefit from traditional therapies.
Future Directions and Research Implications
Funding for this research was allocated in August 2024, with participant recruitment slated to commence in January 2025. By January 2026, the study had enrolled 59 participants, with 51 completing their visits. The findings from this study have the potential to significantly reshape the current understanding and management of COSP, particularly for those patients for whom surface-focused therapies prove inadequate.
This research holds critical implications for public health as it addresses a considerable burden faced by individuals with chronic pain syndromes and aims to enhance treatment pathways. According to the World Health Organization, effective management of chronic pain is vital for improving quality of life and healthcare outcomes.
Reference: De Lott LB et al. Central nervous system mechanisms and treatment response in chronic ocular surface pain: protocol for a cross-sectional observational phenotyping study. JMIR Res Protoc. 2026;15:e84240.
